1. Introduction {#sec1}
===============

Glycogen is a highly branched polymer of glucose (also containing a small but significant amount of protein^[@ref1]^) consisting of linear chains formed by α-(1 → 4) linkages with α-(1 → 6) linkages giving rise to branching points at various intervals. Glycogen provides a unit of energy storage as well as a method of controlling energy release in a myriad of organisms,^[@ref2]^ and impairment of these functions in mammals is a characteristic of numerous diseases, notably diabetes. As a link has been shown to exist between changes in glycogen structure and changes in the rate of energy release^[@ref3]^ (important in diabetes, which is characterized by loss of blood-sugar control^[@ref4],[@ref5]^), the study of the structure of glycogen and the modeling of the biosynthetic processes that give rise to it have been of increasing interest in recent years.

Starch is a similar glucose polymer to glycogen, also formed by α-(1 → 4) and α-(1 → 6) linkages, and consists of two types of component molecules: amylose, composed of relatively few, long-chain branches, and amylopectin, with a comparatively large number of short-chain branches. One of the most easily accessible and useful structural properties that can be extracted from both glycogen and starch is the chain-length distribution (CLD), the molecular abundance of individual chains as measured by the relative number of chains (denoted *N*~de~, obtained by enzymatic debranching of the parent branched molecule) of each degree of polymerization (DP, denoted *X*) present in the polymer. This property is most optimally collected using fluorophore-assisted carbohydrate electrophoresis (FACE), a technique that can provide baseline resolution of chain abundance up to DP 180.^[@ref6],[@ref7]^ The CLD of amylopectin has been extensively studied, and analysis of this structural information has provided valuable insights into the underlying biosynthetic processes that give rise to the polymer and has shed light on structure--property relations.^[@ref8]^ Using parametric models, differences between amylopectin CLDs have been tied to changes in the activities of the metabolic enzymes involved in amylopectin synthesis,^[@ref8]^ sparking interest in using such models to investigate the enzymatic processes involved in glycogenesis.

A previous attempt was made to apply the biosynthetic model for amylopectin developed by Wu et al.^[@ref8]^ to the study of glycogenesis, resulting in a failure to adequately represent the shape of glycogen CLDs in terms of the activities of the enzymes involved in starch biosynthesis.^[@ref9]^ The differences between the experimental data collected and the most similar distributions allowed by the amylopectin model were ascribed in part to the postulate^[@ref10]^ that hindrance is a significant chain-stopping mechanism in glycogen, but other questions regarding the reasons for this discrepancy remain. The strategy employed in this previous attempt retained several assumptions about amylopectin that are uncertain or untrue in the case of glycogen, possibly contributing, along with the effects of hindrance, to the inconsistency between theoretical and experimental results. Herein, we explore the viability of modifying this approach to more accurately reflect the biosynthetic processes involved in glycogenesis with the goal of successfully parameterizing glycogen CLDs in terms of the biosynthetic enzymes involved.

2. Methods {#sec2}
==========

As in the previous attempt mentioned, the biosynthetic model developed by Wu et al. was chosen as a basis for modification due to its excellent parametric fits for amylopectin.^[@ref8]^ This technique models CLDs using a system of differential equations containing terms representing the action of each of the enzymes involved in amylopectin biosynthesis and then solves the matrix form of these equations (which represent the molecular weight distributions of the individual chains of the polymer) using numerical methods to find the number of chains of each DP present for a given set of parameters. Three types of enzymes are considered in the amylopectin model: starch synthase, which linearly adds monomers, starch debranching enzyme, which removes entire chain branches, and starch branching enzyme, which splits branches that meet a certain minimum length and then reattaches the snipped segment as a new branch on either a nearby chain or the stub chain formed by the reaction. Minimum chain length requirements for the stub portion to be retained (*X*~0~) as well as the snipped portion to be detached (*X*~min~) by the branching enzyme are specified as parameters, as is the ratio of branching enzyme to synthase activities (β) and the ratio of debranching enzyme to synthase activities (γ). The model also allows for multiple isoform sets of all three enzymes considered, each with different values of *X*~0~, *X*~min~, β, and γ. As all activities are measured relative to those of synthase, no parameter representing the activity of synthase is needed.

In several species of plants, the normalized CLD of amylopectin in storage organs (e.g., cereal grains) has been shown to be invariant with time for a given plant.^[@ref11]−[@ref13]^ Despite total amounts of the polymer (as represented by the magnitude of the CLD) and relative rates of synthesis and degradation changing throughout the diurnal cycle, this finding shows that the relative abundance of chains of each DP is invariant with time. This allows for what is referred to in the work of Wu et al. as the steady-state assumption (the assumption that the normalized observed CLD in a sample is independent of the time of measurement) and allows for the time-independent form of the equations of Wu et al. to be used, greatly simplifying the process of finding solutions. Although it is not yet known whether the CLD of glycogen is in a steady state, the previous attempt to apply this model to glycogen retained this assumption.^[@ref9]^ As glycogen synthase (GS) is a functional analogue of starch synthase^[@ref14]^ and glycogen branching enzyme (GBE) is a functional analogue of starch branching enzyme,^[@ref15]^ the previous treatment logically retained the original representation of these enzymes in the model. Additionally, however, the previous modeling attempt also retained the original representation of starch debranching enzyme, of which there is no known analogue in glycogen (despite their similar names, glycogen debranching enzyme, abbreviated GDBE, performs a fundamentally different role to starch debranching enzyme and functions as both a glucanotransferase and a glucosidase,^[@ref16]^ acting only on substrates of DP 4 and transferring a DP 3 chain linearly to the end of an existing chain), as well as the possibility of multiple isoforms of GS and GBE, which have not been shown to exist in vivo. These differences between the two compounds may have, along with the effects of hindrance, contributed in part to the observed discrepancy previously reported.^[@ref9]^

In light of the aforementioned, hitherto unrepresented, differences between amylopectin and glycogen metabolism, the first new strategy employed was to disallow multiple enzyme isoforms in the model and to set γ = 0 to effectively remove the debranching enzyme from the system (all variable names have been retained from the previous treatment). This approach would leave single isoforms of GS and GBE as the only enzymes in the system and would not consider the action of any catabolic enzymes, which have previously been hypothesized to be unnecessary to describe the processes in glycogenesis that give rise to glycogen structure in vivo.^[@ref9]^ Numerical solutions of the matrix equations representing the system followed similar methods to those used by Wu and Gilbert,^[@ref17]^ including ensuring that coefficient matrices used were sufficiently large as to reduce the appearance of numerical artifacts from instability in the solving method to acceptable levels. As it has long been postulated that hindrance stops the growth of glycogen by way of hindering the action of the metabolic enzymes to the point where they can no longer perform their functions^[@ref10]^ (a hypothesis supported by the observed spontaneous termination of the growth of synthetic glycogen in vitro in the presence of only GS and GBE^[@ref18]^), this method would represent these hindrance effects as a reduction of the activity of the synthetic enzymes and then adjust the functional forms for these reductions in activities until the characteristic features of typical experimental glycogen CLDs were observed. As will be demonstrated, this approach was not able to be successfully employed and further modifications to the model were required.

3. Results and Discussion {#sec3}
=========================

It was found that this first modification of the model could not yield positive (and therefore valid) values for chain abundance within the typical experimentally accessible range for glycogen CLDs (above DP ≈ 60, the number of chains ordinarily present in glycogen samples is so low as to cause the signal-to-noise ratio of the data to become unacceptably poor) regardless of the values of the parameters chosen. The cause of this was the ratio of β to γ falling within the physically impossible range, as described by Wu and Gilbert.^[@ref17]^ Values of γ low enough to push the ratio of these two variables into this range (e.g., γ = 0) cause the CLD calculated under the steady-state assumption to reach negative values, with negative values appearing earlier in the distribution with lower values of γ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). This result shows that the CLDs of systems with γ = 0 cannot be found using the steady-state solutions of the model of Wu et al., necessitating the exploration of other approaches.

![Plot of theoretical CLDs calculated using the modified Wu et al. model. All series were generated using the following parameters from an example of amylopectin modeling:^[@ref17]^*X*~0~ = 4, *X*~min~ = 7, β = 0.21511746, whereas the original value of γ (0.09329577) was varied to illustrate the appearance of negative values of *N*~de~ at different points in the CLD depending on the value of γ selected (listed in the legend). All series are normalized to have the same maximum value to illustrate the qualitative changes in the shape of the CLD with variations in γ. We note parenthetically that although it is usually best to use a logarithmic *Y* axis for such data, in this particular case, this confers no advantage. A plot of these data without normalization is available in [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00922/suppl_file/ao7b00922_si_001.pdf).](ao-2017-00922v_0004){#fig1}

Although glycogen not being in a steady state is a possible explanation for the previous result, it is important to note that even for values of γ incompatible with a steady state (i.e., in the physically impossible range), no values selected could generate chains of DP below the lower of the two product length requirements of GBE (*X*~0~ and *X*~min~) regardless of whether the CLD obtained corresponded to a physically possible steady-state solution ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). In view of this, and as there were still several unaccounted-for differences between the biosynthetic properties of the metabolic enzymes of amylopectin and glycogen that could be responsible for the observations, further alternatives within the realm of steady-state solutions were explored.

Considering that growth of synthetic glycogen is observed to spontaneously terminate in vitro in the presence of only GS and GBE,^[@ref18]^ it was deemed prudent to determine which values of enzyme activities would be necessary to yield experimentally observed CLDs as results with the steady-state condition still enforced under assumptions more appropriate for the case of glycogen. To this end, γ was set equal to zero, a single isoform set was assumed for both GS and GBE, and values of *X*~0~ and *X*~min~ consistent with those observed for GBE in vitro (6 and 7, respectively) were selected (although these observations did not allow for differentiation between *X*~0~ and *X*~min~, they did determine that the lower of the two values is 6 and the other one is probably 6 or 7).^[@ref19]^ β was allowed to vary depending on the DP (*X*) of the substrate chain being acted upon, and values of β(*X*) were found by modifying the matrix form of the equations used by Wu et al. so that the solution vector consisted of β values for each DP value (*X*) and the coefficient matrix contained experimental values for chain abundance (denoted *N*(*X*) in matrix form rather than *N*~de~(*X*) for visual simplicity). Remaining terms that were independent of β were shifted to the (previously zero) solution vector ([eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"})

This strategy is qualitatively different from that used by Wu, Gilbert, and co-workers in previous treatments.^[@ref8],[@ref17]^ Specifically, instead of assuming values for *X*~0~, *X*~min~, β, and γ and then adjusting them to fit experimental data, experimental data are here used to directly calculate β(*X*) with γ = 0 and for assumed values of *X*~0~ and *X*~min~ from interpretation of in vitro experiments. This yields the dependence of β on the DP of the substrate, which was assumed to be constant in the treatment of Wu et al. for want of applicable experimental data on this dependence (although more recent experiments strongly suggest such a dependence exists^[@ref19]^).

By retaining the assumptions that synthase activity is invariant with substrate DP and that all valid products of the reaction of the branching enzyme with a substrate of a given DP have an equal probability of being formed, this method was applied to create a system of equations in matrix form ([eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}). As is evident through a cursory visual inspection, the system cannot be solved due to the coefficient matrix being singular. Although this may seem paradoxical, as solutions (albeit physically impossible ones) to systems with the same values of *X*~0~, *X*~min~, and γ can be found using the method of Wu et al., the replacement of constant values of β with β(*X*) and the use of *N*~de~(*X*) as input parameters rather than as the solution qualitatively alters the system. By design, the terms representing the loss of chains due to the branching enzyme using them as substrate are not included in the differential equations for chains of DP \< *X*~0~ + *X*~min~, as the branching enzyme is assumed not to be able to act on those chains. Consequently, after allowing β to vary with *X* and converting the equations representing the system to matrix form ([eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}), the system has no dependence on the values of β(*X*) for 1 ≤ *X* \< *X*~0~ + *X*~min~ and thus solutions for these variables cannot be found. The system does, however, have a dependence on values of β(*X*) for *X* ≥ *X*~0~ + *X*~min~, and solutions in this range can be found analytically by truncating the matrix form of the system ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00922/suppl_file/ao7b00922_si_001.pdf)) to eliminate the differential equations containing β(*X*) for 1 ≤ *X* \< *X*~0~ + *X*~min~ (1 ≤ *X* \< 13 in the example given in [eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}).

After first finding analytical solutions for a system with a maximum DP of 50, experimental glycogen CLDs ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) were used to calculate values of β(*X*) for *X* ≥ *X*~0~ + *X*~min~ ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). It was found that all calculated values of β(*X*) in this range were positive and therefore physically possible, although caution should be exercised in interpreting the exact values calculated using this treatment as both the assumptions that the activity of GS has no substrate-length dependence and all valid products of the reaction of GBE on a substrate of a given DP have an equal probability of formation were still in effect.

![Experimental *N*~de~ distributions^[@ref9]^ used to calculate substrate-dependent values for β. Series have been normalized to the same maximum in arbitrary units. Although these data consist of discrete points for each DP, they have been shown here as continuous lines for visual ease.](ao-2017-00922v_0006){#fig2}

![Dependence of β(*X*) on substrate DP (*X*) for the CLDs presented in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} as calculated using the truncated form of [eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}. All calculations were performed using the following parameters: *X*~0~ = 6, *X*~min~ = 7, and a maximum DP of 50 considered. Oscillatory behavior was shown to be artifactual and caused by noise in experimental CLDs used as input data rather than instability in the solving method ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00922/suppl_file/ao7b00922_si_001.pdf)).](ao-2017-00922v_0001){#fig3}

It has been hypothesized that the action of the branching enzyme can be modeled more realistically by allowing it to act on chains shorter than its substrate-length requirement (*X*~0~ + *X*~min~) at a reduced rate.^[@ref17]^ This is easily incorporable into this new treatment by way of removing restrictions on *X*~0~ and *X*~min~, albeit with some caveats. As discussed previously, the data obtained from FACE at DP 1--2 are generally considered unsuitable for interpretation and therefore it is unwise to include terms containing *N*~de~(*X*), where *X* ≤ 2. To exclude terms representing chains of these lengths from the system, the parameter values *X*~0~ = 3 and *X*~min~ = 3 were selected. If the CLD of glycogen is both in a steady state and able to be explained through the action of solely GS and GBE (and hindrance effects reducing the activity of these two enzymes), the values of β(*X*) found by solving this system should decay sharply at *X* ≲ 13 (the approximate sum of the experimentally inferred values of *X*~0~ and *X*~min~).

This was not found to be the case ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), as the solution to the system mandates high values of β(*X*) in this DP to account for the abundance of DP \< 6 chains observed ubiquitously in glycogen CLDs, with changes in *X*~0~, *X*~min~, as well as the highest DP considered in the system having no influence on the appearance of this trend ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00922/suppl_file/ao7b00922_si_001.pdf)). This calculated result is inconsistent with experiments, where no significant change in the abundance of chains of DP \< 6 chains was observed even after prolonged treatment of a substrate of a known distribution with GBE in vitro^[@ref19]^ (which, in the context of the model, fixes the lower of the two values between *X*~0~ and *X*~min~ at 6). This suggests that these short (DP \< 6) chains arise out of the action of an enzyme other than GS and GBE, likely one or both of the two chain-shortening catabolic enzymes (glycogen phosphorylase,^[@ref20]^ abbreviated GP, and α-glucosidase,^[@ref21]^ abbreviated GAA) known to be involved in glycogen metabolism. Although this may seem counterintuitive, as GS can theoretically give rise to chains of DP \> 2 through elongation of chains, the substrate for these reactions cannot be provided by GBE, which can only produce chains as short as DP 6. Therefore, all substrates for reactions that proceed on chains of DP \< 6 (such as the aforementioned elongation by GS) must arise from chain-shortening processes, such as the action of GP or GAA.

![Dependence of β(*X*) on substrate DP (*X*) for the CLDs presented in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} as calculated from the truncated form of [eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"} ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00922/suppl_file/ao7b00922_si_001.pdf)). All calculations were performed using the following parameters: *X*~0~ = 3, *X*~min~ = 3, and a maximum DP of 40 considered.](ao-2017-00922v_0002){#fig4}

Indeed, assays of enzyme activity from mouse liver samples show a significant level of glycogen phosphorylase activity at various points in the diurnal cycle^[@ref22]^ during periods of both glycogen accumulation and depletion,^[@ref23]^ strengthening the case for including catabolic enzymes in the model despite their omission from previous modeling and simulation work.^[@ref3],[@ref9]^ To test what effects the addition of these catabolic enzymes would have on the calculated values of β(*X*), terms representing GP and GAA activity were added to the model. These enzymes essentially perform an opposite function to GS, shortening linear chains by removing one monomer at a time (although the action of GP stalls four monomers away from branch points, GAA is not known to suffer any such restriction^[@ref20]^). Terms of the same form as that of GS (with reversed signs) representing the action of GP and GAA were added to the model, yielding a new coefficient matrix ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00922/suppl_file/ao7b00922_si_001.pdf)), which was then manipulated once again to solve for values of β(*X*).

It was found that, despite their subtly different implementations in the model, the individual values of the ratio of GP to GS activity (δ) and the ratio of GAA to GS activity (ε) had no effect on the values of β(*X*) calculated, even with values of *X*~0~ and *X*~min~ as low as 3 being used as parameters, with only the sum of δ and ε affecting the results obtained ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00922/suppl_file/ao7b00922_si_001.pdf)). The values of the sum of δ and ε were varied to determine if changes in these parameters could reverse the trend observed in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}, where values of β(*X*) were observed to increase sharply below the experimentally established value of *X*~0~ + *X*~min~. Although sufficiently high values of δ + ε were successful in causing a decay in the value of β(*X*) at low DP, they did so at the cost of causing β(*X*) to take on negative (and thus physically impossible) values ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). This is possibly a result of issues arising from the retention of the assumption of equal product formation probability for GBE and the lack of consideration of GDBE in this treatment.

![Effects of the addition of terms representing the action of chain-shortening enzymes on the values of β(*X*) previously calculated in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}. Sufficiently large sums of δ + ε, in this case, δ + ε = 30, cause values of β(*X*) to decay at low values of *X*, consistent with physical predictions, although other, unknown, factors cause β(*X*) to take on disallowed negative values at higher values of δ + ε ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00922/suppl_file/ao7b00922_si_001.pdf)).](ao-2017-00922v_0005){#fig5}

Due to the action of GDBE depending on two values of *N*~de~(*X*), one for the chain acted upon by the glucosidase function of the enzyme and another for the chain acted upon during the subsequent glucanotransferase reaction, equations representing the action of GDBE would contain nonlinear terms and are not compatible with models of this nature. Neglecting to include a representation of GDBE in this treatment, however, is unlikely to qualitatively change the observed trend in the value of β(*X*) due to its action being mathematically indistinguishable from a loss of DP 4 chains and linear addition of monomers analogous to the action of GS. Thus, it is likely that calculated values of β(*X*) using a model that was able to successfully represent GDBE would depend primarily on the sum of GS and GDBE activity, rather than the individual values, similar to the case in this treatment, where only the sum of δ and ε impacted the values of β(*X*) obtained.

4. Conclusions {#sec4}
==============

A qualitative re-treatment of the steady-state solutions of the model developed by Wu et al. has been developed, as the original treatment cannot adequately describe glycogen CLDs. The new treatment enables an assumption made in the absence of detailed information in the original treatment to be overturned: instead of using a constant value of the enzyme-activity ratio β and varying this value to fit data via trial-and-error method, the new methods calculates the dependence of β on DP through a novel means of processing experimental in vivo data.

Application of this technique to experimental glycogen CLDs yielded results that showed that chain-shortening events in vivo, probably caused by the action of the catabolic enzymes glycogen phosphorylase and/or α-glucosidase, must be responsible for the presence of chains shorter than the minimum product length requirement for GBE that has been demonstrated in vitro ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Although this result does not cast doubt on previous conclusions of hindrance being a major contributor of chain stoppage in glycogen, hindrance can only explain eventual stoppage of chain growth (and thus, growth of the molecule) and cannot explain the chain-shortening processes that the present work has demonstrated must be occurring to yield the CLDs experimentally observed.

###### Summary of the Possible Origins of Chains Lengths Observed in Experimental Glycogen CLDs[a](#t1fn1){ref-type="table-fn"}

         possible product of the action of:                     
  ------ ------------------------------------ ----- ----- ----- -----
  1      no                                   no    no    yes   no
  2--3   yes, from DP 1--2 substrate          no    no    yes   no
  4--5   yes, from DP 3--4 substrate          no    yes   yes   yes
  6+     yes                                  yes   yes   yes   yes

Although short chains (DP 2--6) can arise from the action of GS, they must do so by using chains of DP 1--5 as substrates. As chains of DP 1--3 can only arise from the action of GAA and chains of DP 4--5 can only arise from the action of GP, GAA, or GDBE, this necessitates the consideration of these catabolic enzymes (GP, GAA, and GDBE) in future attempts to represent the biosynthetic origins of glycogen CLDs, given that chains of DP 1--5 are ubiquitously observed in analyzed samples.

Future work is needed to elucidate any substrate preferences of the other metabolic enzymes considered in the model and to determine the product preferences of the reaction of GBE so these calculated substrate preferences of GBE can be more meaningfully interpreted. Before the effects of hindrance can be incorporated into future biosynthetic models of this nature, the effects of catabolic enzymes capable of giving rise to these short chains, as well as GDBE (which is capable of removing DP 4 chains and subsequently elongating chains of any length via a glucanotransferase reaction) must be considered. Doing this will open the possibility of finding functional forms for the enzyme-specific effects of hindrance as a function of localized density, advancing understanding of the processes underlying glycogen biosynthesis and their relationship to glycogen-storage diseases, such as diabetes.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.7b00922](http://pubs.acs.org/doi/abs/10.1021/acsomega.7b00922).Additional forms of matrix equations, plots, and model calculations illustrating the effects of changing parameters of the model ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00922/suppl_file/ao7b00922_si_001.pdf))
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